This article aims to address updates on recent clinical trial findings (April 2019 to April 2020) regarding biologic therapy initiation and maintenance for adult patients. Prescribers should use this update as guidance for determining the appropriate biologic class based on patient characteristics and for approaching biologic-experienced patients with refractory psoriasis. This update also may serve as a reference for the recommended dosing regimens of the 11 approved biologics.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.12788/cutis.0035 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!